Mutations in Triple Negative Essential Thrombocytopenia Detected

Share this content:
Atypical mutations were found in the thrombopoietin receptor in patients with triple negative essential thrombocytopenia.
Atypical mutations were found in the thrombopoietin receptor in patients with triple negative essential thrombocytopenia.

Atypical mutations were found in the thrombopoietin receptor (MPL) in patients with triple negative essential thrombocytopenia (ET), according to an article published online ahead of print in Blood.1

Investigators used whole exome sequencing and next generation sequencing to detect mutations in 17 ET samples that were negative for JAK2V617F, MPLW515K/L, and CALR mutations. JAK2V617F at low-allele frequency, two MPLS204P signaling mutations, and one of each of the following signaling mutations: SH2B3, MPLS505N, MPLW515R, were found.

Clonal and polyclonal hematopoiesis were detected in four and seven samples, respectively. This suggests that some cases of triple-negative ET are not myeloproliferative neoplasms.

After next genome sequencing on an additional 26 triple-negative samples, only one MPLY591N mutation was detected and was found to be a weak gain-of-function. MPLS204P was also found to be weak gain-of-function after functional studies.

RELATED: New Insights into the Association Between Renal Cell Carcinoma, Hematologic Malignancies

These mutations increase MPL signaling and may induce TPO hypersensitivity or function without expressing cells, but with little effect.

Investigators suggest additional studies to determine the frequency of MPLS204 and MPLY591 in a larger cohort of triple-negative ET patients.

Reference

  1. Cabagnols X, Favale F, Pasquier F, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple negative essential thrombocytopenia patients [published online ahead of print October 8, 2015]. Blood. doi: 10.1182/blood-2015-07-661983.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters